GlassScriptPhysician profile
Skyler S Meyer
NPI 1952673709
$746.26
in general payments reported to CMS, 2019-2025
15 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $289 · 2024: $189 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703 · Entertainment: $43.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.26 |
| Entertainment | $43.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $133.71 | 2023-2024 | Trelegy Ellipta, Shingrix, Bexsero |
| Abbvie INC. | $115.52 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $99.51 | 2023-2025 | Rexulti, Abilify Maintena |
| Indivior INC. | $69.00 | 2023-2024 | Sublocade |
| Novo Nordisk INC | $48.59 | 2023-2025 | Wegovy, Ozempic |
| Optos, INC. | $43.00 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Axsome Therapeutics, INC. | $41.35 | 2023-2024 | Auvelity |
| Pfizer INC. | $35.31 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $34.35 | 2023-2024 | Airsupra, Farxiga |
| Exact Sciences Corporation | $28.45 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $22.50 | 2024 | Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $22.08 | 2025 | Cobenfy |
| Lilly USA, LLC | $18.72 | 2023 | Mounjaro |
| Vanda Pharmaceuticals INC. | $18.53 | 2024 | Fanapt |
| Alkermes, INC. | $15.64 | 2025 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skyler Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.